Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New combo therapy aims to outsmart liver Cancer's hiding spots

NCT ID NCT04862949

Summary

This study looked at whether a combination of two drugs (atezolizumab and bevacizumab) could better control advanced liver cancer, especially tumors located in the liver itself. Researchers tested this in 131 patients with advanced liver cancer who had not yet received other drug treatments. The main goal was to see if the treatment worked differently on cancer in the liver versus cancer that had spread to other organs.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Cha Medical Center

    Seongnam-si, Gyeonggi-do, 13496, South Korea

Conditions

Explore the condition pages connected to this study.